Clementia starts Phase III of palovarotene to treat FOP

Clementia Pharmaceuticals Inc. (Montreal, Quebec) began the Phase III MOVE trial to evaluate oral palovarotene (R667) in 80 patients with fibrodysplasia ossificans progressiva (FOP). The company plans to complete enrollment by the end of next year with top-line data expected in late 2020.

Patients will receive once-daily 5 mg palovarotene for up to 24 months for chronic treatment of FOS. Patients can also receive once-daily 20 mg palovarotene for four weeks followed by 10 mg palovarotene for eight weeks to treat FOS flare-ups. ...